| Environmental Phthalate Exposures In Pregnancy in Relation to Fetal and Placental Development |
Research Initiative |
CDC |
NIEHS |
The purpose of this collaboration is to characterize exposure to phthalates and phthalate alternatives in pregnant women by measuring phthalate and phthalate alternative metabolites in urine samples from 8 visits in pregnancy. We will examine associations between these markers and fetal growth as well as ultrasound measures of placental development. |
| eRA Federal Shared Services |
Resource Development |
ARPA-H, AHRQ, ASFR, FDA, SAMHSA |
OD/OER |
Grants Quality Service Management Office (Grants QSMO) Marketplace solution provider. Collaboration with other HHS agencies and federal agencies to provide electronic Research Administration (eRA) grants management services and support across the full grants life cycle. |
| Establishment of representative examination and dose repository for patients undergoing interventional fluoroscopic procedures |
Research Initiative |
FDA |
NCI |
NCI and FDA investigators are collaborating to establish representative examination and organ doses for fluoroscopically-guided interventional procedures by collecting anonymized patient data from multiple US clinical institutions. |
| Estrogen Metabolism Pathways in Pregnancy and Maternal Breast Cancer Risk: A Prospective Follow-up Study |
Research Initiative |
FDA |
NCI |
In the years following pregnancy, breast cancer risk is elevated, particularly for hormone receptor negative (HR-) tumors. Exposure to high maternal circulating estrogens, when the breast is vastly remodeling in structure and morphology, has been associated with risk, particularly for HR- tumors. Estrogen metabolite profiles in nonpregnant women, notably the ratio of 2:16 hydroxylation (OH) pathway metabolites, are associated with postmenopausal breast cancer development; whether estrogen metabolism during pregnancy influences subsequent HR- breast cancer risk is unknown. DCEG is collaborating with FDA on this project. |
| Evaluation of Oropharyngeal responses to SARS-CoV-2 |
Research Initiative |
FDA |
NIAID |
Evaluation of Oropharyngeal responses to SARS-CoV-2 |
| Evidence-based Cancer Control Programs |
Resource Development |
CDC |
NCI |
The Evidence-based Cancer Control Programs website is a searchable database of cancer control interventions and program materials and is designed to provide program planners and public health practitioners easy and immediate access to research-tested materials. |
| Executive Committee for Acquisitions |
Committee, Work group, Advisory group, or Task Force |
ASFR, CDC, FDA, HRSA |
OD/OM, OD/OM/OALM |
The Executive Committee for Acquisitions meets under the leadership of the HHS Senior Procurement Executive (SPE) and includes all the Heads of Contracting Activities from the various HHS Operating Divisions. The purpose is to receive policy updates and collaborate on acqusiition related issues. |
| Exploring T Cell functional dynamics following low-dose radiation exposure: insights into metabolic and other regulatory alterations using a multi-omics systems biology approach |
Research Initiative |
FDA |
NCATS |
Low-dose radiation studies studies are challenging because molecular responses can be modest at best, so choice of in vivo model systems is critical. The planned studies on T cells in mice and humanized mice are highly significant since we have already documented clear measurable responses in DOE’s preferred dose range. In the case of relevance to exposed populations, both shorter- and long-term immune effects impact human health, as documented in human population studies after LDR. As will be discussed, a critical component of immune responses is dependent on T cell subsets and metabolic programming is a central component for T cell activation and differentiation. Thus, this proposal will focus on T-cell perturbations after LDR with emphasis on elucidating signaling and metabolic pathways involved and robustly evaluating associations between responses at the different omic levels. To enable reuse and enhance utility of the comprehensive multi-omic datasets produced, we will provide public access to LDR-specific molecular responses from in our models and thus readily enable integration of our data with complementary data from other programs, such as the Low-dose Understanding, Cellular Insights, and Molecular Discoveries (LUCID) program. All data and code will be made publicly available to ensure reproducibility and reuse of the data by the broader radiation community. |
| FDA Center for Drug Evaluation (CDER)/NIDA Division of Therapeutics and Medical Consequences (DTMC) |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIDA |
Collaboration between the FDA Center for Drug Evaluation (CDER)/NIDA Division of Therapeutics and Medical Consequences (DTMC). |
| FDA Device Workgroup |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIMH |
This workgroup provides ongoing dialogue with the Food and Drug Administration (FDA) related to devices and mHealth. |